The use of insulin secretagogues in the treatment of type 2 diabetes

Primary Care - Clinics in Office Practice

Volumn 26, Issue 4, 1999, Pages 895-915

  Luna, B ^a   Hughes, A T D ^a   Feinglos, M N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; ERYTHROMYCIN; FLUCONAZOLE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE; ISONIAZID; KETOCONAZOLE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; EXERCISE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY FAILURE; LIVER TOXICITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 0032739138     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(05)70138-X     Document Type: Article

References (63)

1. F. Abbasi V. Kamath A. Rizvi Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients: Evidence for a central role of adipose tissue Diabetes Care 20 1997 1863 1869
2. B. Ahren H. Larsson J.J. Holst Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 82 1997 473 478
3. K. Asplund B.-E. Wilholm F. Lithner Glibenclamide-associated hypoglycaemia: A report on 57 cases Diabetologia 24 1983 412 417
4. A. Baron C. Neumann on behalf of the PROTECT Study Group PROTECT interim results: A large multicenter study of patients with type 2 diabetes Clin Ther 19 1997 282 295
5. M. Bayraktar N. Adalar D.H. Van Thiel A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients Diabetes Care 19 1996 252 254
6. P.J. Bijlstra J.A. Lutterman F.G. Russel Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans Diabetologia 39 1996 1083 1090
7. A.E. Boyd III L. Aguilar Bryan D.A. Nelson Molecular mechanisms of action of glyburide on the beta cell Am J Med 89 1990 3S 10S
8. M. Burge K. Schmitz-Fiorentino C. Fischette A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus JAMA 279 1998 137 143
9. J.L. Chiasson R.G. Josse J.A. Hunt The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus Ann Intern Med 121 1994 928 935
10. R.F. Coniff J.A. Shapiro T.B. Seaton Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus Am J Med 98 1995 443 451
11. P. Damsbo P.H. Anderson S. Lund Improved glycemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstract 0132] Diabetes 46 suppl 1 1997 34A
12. R.A. DeFronzo A.M. Goodman Multicenter Metformin Study Group Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 541 549
13. D.J. Dills J. Schneider The Glimepiride/Glyburide Research Group Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study Horm Metab Res 28 1996 426 429
14. R. Engler D. Yellon Sulfonylurea K-ATP blockade in type 2 diabetes and preconditioning in cardiovascular disease: Time for reconsideration Circulation 94 1996 2297 2301
15. M.N. Feinglos M.A. Bethel Treatment of type 2 diabetes mellitus Med Clin North Am 82 1998 757 791
16. J. Fuhlendorff R.D. Carr H. Kofod Repaglinide: Unique mechanism of action in normal and metabolic stressed β cells [abstract 754] Diabetologia 38 suppl 1 1995 A195
17. J. Fuhlendorff P. Rorsman H. Kofod Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes Diabetes 47 1998 345 351
18. J.E. Gerich Oral hypoglycemic agents N Engl J Med 321 1989 1231 1245
19. N. Gitlin N.L. Julie C.L. Spurr Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone Ann Intern Med 129 1998 36 38
20. R.B. Goldberg R.G. Brodows P. Damsbo A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes Diabetes Care 21 1998 1897 1903
21. R.B. Goldberg S.M. Holvey J. Schneider A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents Diabetes Care 19 1996 849 856
22. M.K. Gutniak H. Larsson S.W. Sanders GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions Diabetes Care 20 1997 1874 1879
23. V. Hatorp G. Haug-Pihale A comparison of the pharmacokinetics of repaglinide in healthy subjects with that in subjects with chronic liver disease [abstract 1375] Diabetes 47 suppl 1 1998 A356
24. R.J. Heine Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II “The cons.” Horm Metab Res 28 1996 522 526
25. J.J. Holst C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670
26. E.S. Horton F. Whitehouse M.N. Ghazzi Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes Diabetes Care 21 1998 1462 1469
27. Y. Iwamoto K. Kosaka T. Kuzuya Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone Diabet Med 13 1996 365 370
28. Y. Iwamoto K. Kosaka T. Kuzuya Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19 1996 151 156
29. M. Janbon J. Chaptal A. Vedel J. Scaap Montpellier Med 441 1942 21 22
30. A.M. Jennings R.M. Wilson J.D. Ward Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents Diabetes Care 12 1989 203 208
31. R. Landgraf H. Bilo Repaglinide versus glibenclamide: A 14-week efficacy and safety comparison [abstract 0626] Diabetes 46 supp 1 1997 162A
32. H.E. Lebovitz α-glucosidase inhibitors as agents in the treatment of diabetes Diabetes Reviews 6 1998 132 145
33. T.C. Marbury V. Hatorp Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers [abstract 1381] Diabetes 47 suppl 1 1998 A357
34. T.C. Marbury W.C. Huang P. Strang Repaglinide versus glyburide: A 1-year comparison trial Diab Res Clin Practice 43 1999 155 166
35. S. Marena V. Tagliaferro G. Montegrosso Metabolic effect of metformin addition to chronic glibenclamide treatment in type 2 diabetes Diabetes Metab 20 1994 15 19
36. A.D. Mooradian S.G. Albert M. Bernbaum The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM Diabetes Care 19 1996 883 884
37. R. Moses R. Slobodniuk S. Boyages Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 22 1999 119 124
38. M.A. Nauck J.J. Holst B. Willms Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus Horm Metab Res 29 1997 411 416
39. B.A. Neuschwander-Tetri W.L. Isley J.C. Oki Troglitazone-induced hepatic failure leading to liver transplantation. A case report Ann Intern Med 129 1998 38 41
40. F. Ovalle D.S.H. Bell Triple Oral Antidiabetic therapy in type 2 diabetes mellitus Endocrine Practice 4 1998 146 147
41. A. Panahloo V. Mohamed-Ali C. Andres A.E. Denver J.S. Yudkin Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes Metabolism 47 1998 637 643
42. Prandin (repaglinide) package insert December 1997 Novo Nordisk Pharmaceuticals, Inc. Princeton, NJ
43. V. Profozic D. Babic I. Renar Benzoic acid derivative hypoglycemic activity in non-insulin dependent diabetic patients [abstract 701] Diabetologia 36 suppl 1 1993 M103
44. G.M. Reaven P. Johnston C.B. Hollenbeck Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control J Clin Endocrinol Metab 74 1992 1020 1026
45. M. Riddle P. McDaniel L. Tive Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM Diabetes Care 20 1997 992 994
46. S.L. Schwartz R.B. Goldberg P. Strange Repaglinide in type 2 diabetes: A randomized, double-blind, placebo-controlled, dose-response study [abstract 0382] Diabetes 47 suppl 1 1998 A98
47. C. Seifarth J. Bergmann J.J. Holst Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in type 2 diabetic patients Diabet Med 15 1998 485 491
48. H.S. Seltzer Drug-induced hypoglycemia: A review of 1418 cases Endocrinol Metab Clin 18 1989 163 183
49. R.I. Shorr W.A. Ray J.R. Daugherty Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas Arch Intern Med 157 1997 1681 1686
50. D.C. Simonson I.A. Kourides M. Feinglos H. Shamoon C. Fischette The Glipizide Gastrointestinal Therapeutic System Study Group Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials Diabetes Care 20 1997 597 606
51. P. Smits Cardiovascular effects of sulfonylurea derivatives Diabetologia 40 1997 S160 S161
52. G. Sonnenberg D. Garg D. Weidler Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus Ann Pharmacother 31 1997 671 676
53. F. Tomai F. Crea A. Gaspardone F. Versaci R. De Paulis A. Penta de Peppo L. Chiariello P.A. Gioffre Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker Circulation 90 1994 700 705
54. P. Damsbo P. Clauson T.C. Marbury A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients Diabetes Care 22 1999 789 794
55. United Kingdom Prospective Diabetes Study Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33) Lancet 352 1998 837 853
56. United Kingdom Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS-34) Lancet 352 1998 854 865
57. University Group Diabetes Program A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Mortality results Diabetes 19 1970 785 830
58. L.F. Van Gaal K.L. Van Acker P. Damsbo Metabolic effects of repaglinide, a new oral hypoglycemic agent in therapy-naive type 2 diabetics [abstract 164] Diabetologia 38 suppl 1 1995 A43
59. W. Waldhausl Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part 1. The pros Horm Metab Res 28 1996 517 521
60. P.B. Watkins R.W. Whitcomb Hepatic dysfunction associated with troglitazone N Engl J Med 338 1998 916 917
61. B.H.R. Wolffenbuttel L. Nijst J.P.J.E. Sela Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in patients with NIDDM Eur J Clin Pharmacol 45 1993 113 116
62. B.H.R. Wolffenbuttel R. Langraf The Dutch and German Repaglinide Study Group A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes Diabetes Care 22 1999 463 467
63. I. Yokoyama S.-I. Momomura T. Ohtake Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus J Am Coll Cardiol 30 1997 1472 1477